A compound of formula I or II, ** Formula ** or a pharmaceutically acceptable salt or solvate thereof, wherein Ring C is selected from oxazolyl and triazolyl； Ring D is selected from phenyl and pyridyl； A is phenyl or a 5- or 6-membered heteroaryl, wherein the phenyl is optionally fused to a 5- or 6-membered heterocyclyl or 5- or 6-membered heteroaryl, wherein A is optionally substituted with 1, 2 or 3 RA groups, wherein each RA is independently RA1, -C1-C6 alkyl-RA1, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, pyrrolidinone or pyrrolidinyl, wherein the cycloalkyl is optionally substituted with 1, 2, 3 or 4 groups which are independently RA1, C1-C6 alkyl or-C1-C6 alkyl-RA1, wherein each RA1 is independently halogen, cyano, nitro, -OR, -NR2, -SR, -C (O) R or -C (O) OR； alternatively, two RAs in adjacent carbons can be joined to form an -O-CH2-O-, -O-CH2-CH2-, -O-CH2-CH2-O-, -CH2-CH2-CH2- or -O- CF2-O-； RB1 is hydrogen, C1-3 alkyl, halo, cyclopropyl, or C1-3 haloalkyl； RB2 is hydrogen, halo, -CN, -C (O) NR2, or C1-3 alkyl； RB3 is C1-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl, each of which is substituted with 0-1 RB5； hydrogen； cyano； -C (O) -R； -C (O) NR2； -NHC (O) R； -NHSO2R； or a 5-membered ring heteroaryl, wherein the heteroaryl ring consists of carbon atoms and 1, 2 or 3 heteroatoms independently selected from the group consisting of N, S and O and is substituted with 0-1 R； RB4 is H, halogen, C1-3 alkyl, C1-3 haloalkyl, -C3-C6 cycloalkyl, or -O-C1-3 alkyl； RB5 is cyano, -OR, -C (O) NR2, -C (O) OR, -NR2, -OC (O) -NH2, -S (O) 2NR2, or a 5-membered ring heteroaryl, wherein the heteroaryl ring consists of carbon atoms and 1, 2 or 3 heteroatoms independently selected from the group consisting of N, S and O； R is hydrogen, halogen, cyano or nitro； n is 0, 1, 2, 3 or 4； and each RD1 and RD2 are independently RD3, C1-C6 alkyl, -C1-C6-RD3 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C3-C8 cycloalkyl, wherein the cycloalkyl i
